Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | DRD1 | P21728 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 5/20 | 0.40 |
| ▸ | DRD5 | P21918 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9284139 | 0.81 | KDM1A (0.44) | SIGMAR1 | |
| SCHEMBL15003306 | 0.80 | KDM1A (0.49) | SIGMAR1DRD2 | |
| SCHEMBL13379624 | 0.76 | ESR1 (0.36) | SIGMAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL9145947 | 0.76 | RXRA (0.41) | — | |
| SCHEMBL10590671 | 0.73 | PGR (0.51) | SIGMAR1DRD2DRD1DRD4DRD5 | |
| SCHEMBL11266819 | 0.73 | SIGMAR1 (0.44) | SIGMAR1DRD2DRD3OPRM1 | |
| SCHEMBL6711237 | 0.73 | ALDH1A1 (0.46) | SIGMAR1OPRM1NR1H2NR1H3 | |
| SCHEMBL2777451 | 0.71 | KDM1A (0.41) | — | |
| SCHEMBL13379635 | 0.71 | ESR1 (0.37) | SIGMAR1 | |
| SCHEMBL24615634 | 0.70 | AKR1C1 (0.39) | SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013096971-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | GFPT1, NUDT1, INF2 | SIGMAR1 734/4885ALOX5AP 3077/4885DRD2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.